Clinical follow-up of long nontapered sirolimus-eluting coronary stent in real-world patients with de novo lesions. The Billar registry

• Published in: REC, Interventional cardiology (Internet. English ed.) Vol. 4; no. 1; pp. 27 - 32
• Main Authors: Domingo Ribas, Enric, Guindo, Josep, Calviño Santos, Ramón, Otaegui, Imanol, Antoni Gómez, Joan, Carrillo Suárez, Xavier, Sánchez, Juan, Andraka, Leire, Torres, Alfonso, Casanova-Sandoval, Juan, Ocaranza Sánchez, Raymundo, León Jiménez, Javier, Francisco Muñoz, Juan, Trillo Nouche, Ramiro, Fuertes, and, Mónica, del Blanco, Bruno García
• Format: Journal Article
• Language: English
• Published: Permanyer 09.02.2022
• Subjects: Coronary angioplasty; Drug-eluting stent; Nontapered stents
• ISSN: 2604-7322; 2604-7322
• DOI: 10.24875/RECICE.M21000251

ABSTRACT Introduction and objectives: Coronary lesions with stent overlapping are associated with higher neointimal proliferation that leads to more restenosis. Furthermore, the tapering of coronary arteries is a major challenge when treating long coronary lesions. This study attempted to assess the safety and clinical level of performance of long nontapered sirolimus-eluting coronary stent systems (> 36 mm) to treat long and diffused de novo coronary lesions in real-world scenarios. Methods: This was a prospective, non-randomized, multicentre study that included 696 consecutive patients treated with the long nontapered BioMime sirolimus-eluting coronary stent system in long and diffused de novo coronary lesions. The safety endpoint was major adverse cardiovascular events defined as a composite of cardiac death, myocardial infarction, clinically driven target lesion revascularization, stent thrombosis, and major bleeding at the 12-month follow-up. Results: Of a total of 696 patients, 38.79% were diabetic. The mean age of all the patients was 64.6 ± 14 years, and 80% were males. The indication for revascularization was acute coronary syndrome in 63.1%. A total of 899 lesions were identified out of which 742 were successfully treated with long BioMime stents (37 mm, 40 mm, 44 mm, and 48 mm). The cumulative incidence of major adverse cardiovascular events was 8.1% at the 12-month follow-up including cardiac death (2.09%), myocardial infarction (1.34%), and total stent thrombosis (0.5%). Conclusions: This study confirms the safety and good performance of long nontapered BioMime coronary stents to treat de novo coronary stenosis. Therefore, it can be considered a safe and effective treatment for long and diffused de novo coronary lesions in the routine clinical practice.